

SCIENTIFIC PROGRAM



ANZSA
Australia and New Zealand
Sarcoma Association

2025 ANNUAL SCIENTIFIC MEETING
10-11 OCTOBER 2025
Crowne Plaza, Hobart & Online

WELCOME

INTERNATIONAL SPEAKER

On behalf of the Australia and New Zealand Sarcoma Association (ANZSA) Chair and ASM Organising Committee, we are delighted to welcome you to the 2025 ANZSA Annual Scientific Meeting, held this year at the Crowne Plaza Hobart, Tasmania, on Friday 10th – Saturday 11th October 2025.

We look forward to another exciting and enriching meeting as we come together to share knowledge, foster collaboration, and strengthen our collective efforts to improve outcomes for sarcoma patients across our region and beyond.


This year's theme, "**United Against Sarcoma: Collaboration and Innovation**," reflects our commitment to harnessing the power of research, multidisciplinary care, and community engagement to drive meaningful change in the sarcoma landscape.

We are honored to welcome Dr. Jason T. Yustein, Professor and Director of the Solid Tumor Translational Research Program at Emory University School of Medicine, as our international guest speaker.

We encourage you to take full advantage of the opportunities to network, exchange ideas, and collaborate with colleagues from all facets of the sarcoma community – including researchers, clinicians, allied health professionals, and patient advocates.

Thank you for being part of the 2025 ANZSA ASM. Your ongoing dedication, insights, and passion are at the heart of our progress.

Warm regards,
The 2025 ANZSA ASM Organising Committee



DR JASON YUSTEIN

**Professor, Department of
Pediatrics
Winship Cancer Institute
Emory University
Georgia, USA**

Jason T. Yustein, MD, PhD, is a professor in the Department of Pediatrics at Emory University School of Medicine. Dr. Yustein is a pediatric oncologist and physician-scientist at Children's Healthcare of Atlanta.

Dr. Yustein is a member of the Discovery and Developmental Therapeutics Research Program at Winship. His research focuses on understanding the mechanisms of metastasis and therapeutic resistance in pediatric sarcomas, including osteosarcoma, Ewing sarcoma, and rhabdomyosarcoma. His laboratory employs innovative murine models and patient-derived resources to gain molecular insights into sarcoma initiation, development, and metastatic progression. These findings are then translated into preclinical testing of novel therapeutic interventions.

A notable aspect of Dr. Yustein's work includes the development of specialized mouse models that closely resemble human osteosarcoma. These models allow for the study of cancer growth and response to treatments, providing valuable tools for testing new therapies.

Dr. Yustein's contributions to sarcoma research have been recognized through various grants and collaborations, reflecting his commitment to advancing the understanding and treatment of pediatric sarcomas.

FRIDAY 10 October

8.00am Registration and exhibition open

9.00am	Welcome address	Fiona Maclean
9.10am	Opening address	Senator Wendy Askew
9.20am	Consumer presentation	Natalia Dewiyani

Session 1: Clinical Research and Innovations

Chair: Angela Hong

9.30am	The Martin Tattersall Lecture: Innovative pre-clinical models to gain insights into sarcoma biology and assessment of novel therapeutic approaches	Jason Yustein
10.15am	NZ National Guidelines	Joanna Connor/Sarah Cheung
10.30am	Rehabilitation after limb salvage surgery - how can we best prepare and manage patients?	Elizabeth Villalta
10.50am	Panel discussion	

11.00am Morning tea

Session 2: Advances in the pathology of BST

Chair: Gelareh Farshid

11.20am	Update on sarcoma subtypes	Alison Cheah
11.40am	Cutaneous undifferentiated malignancies	Catherine Mitchell
11.50am	UK guidelines for management of bone and soft tissue sarcomas	Deborah Gomes
12.00pm	Updated recommendations for the assessment of peripheral nerve sheath tumours in NF1 patients	Gelareh Farshid
12.20pm	Access to Molecular Diagnostics for sarcomas in Australia	Alex Jolley
12.35pm	Moderated Q&A	

1.00pm Lunch

ANZSA Annual General Meeting (AGM members only)	Adrian Cosenza
---	----------------

Session 3: Advances in Sarcoma Research

Chair:
Fernando Guimaraes

2.00pm	Cross-species approaches for identifying and testing novel therapeutic interventions for high-risk pediatric sarcomas	Jason Yustein
2.30pm	The Childhood Cancer Model Atlas: a preclinical resource to identify novel therapies	Paul Daniel
2.50pm	Spatial profiling of tumour microenvironment uncovers potential novel therapeutic approach in paediatric rhabdomyosarcoma	Cui (Maxine) Tu
3.05pm	Surgery is a window of opportunity: delivering intra-operative immunotherapy to prevent post-surgical recurrence	Ben Wylie
3.20pm	Panel - Sarcoma research is the best	Fernando Guimaraes



Waterfront Wander
7am group walk Saturday

FRIDAY 10 October

SATURDAY 11 October

3.50pm Presentations from selected abstracts Chair: Joanna Connor

3.50pm	A Novel Therapeutic Strategy for Osteosarcoma Using Anti-GD2 ADC and EZH2 Inhibitor	Jing Shan
3.55pm	Genome-wide pooled genetic screening reveals mediators of cisplatin resistance in osteosarcoma.	Jason Cain
4.00pm	Mapping the Immunopeptidome of Paediatric Ewing Sarcoma to Enable T Cell-Based Therapies.	Grace Huang
4.05pm	Comparing rates of nausea in patients who received IV Mesna versus Oral mesna with ifosfamide chemotherapy- A retrospective analysis	Tenny Sunny
4.10pm	Recurrence Patterns and Survival Across Histological Subtypes of Abdominal Soft Tissue Sarcomas: A Retrospective Single-Centre Study	Bernard Hanekom
4.15pm	Reoperations and recurrence following surgery for myxofibrosarcoma – a major Australian sarcoma centre experience	Mukund Karthik
4.20pm	Discussion	

4.30pm Refreshments and poster viewing

5.30pm End day 1

ANZSA GALA DINNER | Friday 10 October | 7pm
Waterline Restaurant



Waterfront Wander
7am group walk

8.00am Registration and exhibition open

8.15am	MINI SESSION: Using Patient Reported Outcome Measures in Cancer Clinical Trials: Prospectives For and Against a 'Modular Approach'	Carrie Ng
--------	---	-----------

Session 4: The role of AI in Early Sarcoma – Whoa to Go Chair: Fiona Maclean

8.45am	Intro: The State of Play	Fiona Maclean
9.05am	AI in Radiology – use cases in musculoskeletal imaging	Catherine Jones
9.35am	AI in Radiation Oncology: status and future	Vanessa Panettieri
9.55am	AI in planning and contouring	Mihir Shanker
10.15am	AI in clinical practice	Peter Grimison
10.35am	Panel discussion and Q&A	

10.50am Morning tea

Session 5: Integrating Palliative Care into Sarcoma Treatment Pathways Chair: Vivek Bhadri

11.10am	Cancer, Sex, Drugs and Death (virtual recorded)	Toni Lindsay
11.40am	The role of AYA hospice	Abigail Franklin
11.55am	Benefits of early integration of supportive palliative care	Kasia Chmiel
12.10pm	Collaboration across services in AYA palliative care	Naomi Katz
12.25pm	Discussion	

SATURDAY 11 October

12.40pm Lunch

Community Connect

		Chair: Sarah Cheung
12.45pm	Introduction and welcome	Sarah Cheung
12.55pm	Tips and Tricks to cope with fear of recurrence (virtual recorded)	Toni Lindsay
1.10pm	Identifying new immunotherapy approaches for liposarcoma	Ian Parish

1.30pm Networking High Tea

Session 6: Challenges in Paediatric vs Adult Sarcoma Management **Chair: Liz Connolly**


1.30pm	Feasibility and outcomes of adult Ewing sarcoma, osteosarcoma and rhabdomyosarcoma treatment with paediatric standards of care – a systematic review	Natacha Omer
1.45pm	Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma	Yeh Chen Lee
2.05pm	Caught in the middle: Challenges in treating the AYA sarcoma population	Jason Yustein
2.25pm	Panel discussion	

Session 7: The Great Debate **Chair: Angela Hong**

2.40pm	The best care can happen only in the big city! Centre based care vs shared care with regional sites	David Coker vs. Hilde Kleiven
3.00pm	Consumer panel: Pros and Cons of going to the city for treatment - a patient perspective	ANZSA Consumer Advisory Panel members


Session 8: Awards and Close **Chair: Jason Cain**

3.15pm	Judges' awards and closing address	
3.30pm	Afternoon tea End of conference	




Community Connect


Saturday 11 October 2025, Crowne Plaza, Hobart & Online



Sarah Cheung
Consumer Advisory
Panel Chair



Dr. Toni Lindsay
Senior Clinical
Psychologist



Dr. Ian Parish
Fundamental
Immunologist

sarcoma.org.au/pages/2025-asm/community-connect-2025

Posters

No.	Title	Presenter
1	A single-cell transcriptomic and functional genomics approach to develop targeted combination therapies for the treatment of osteosarcoma	Tiruneh Adane Birlie
2	Multi-omics analysis of childhood, adolescent and young adult osteosarcoma to identify molecular prognostic and therapy resistance signatures.	Jason Cain
3	Revealing the immunosuppressive microenvironment in paediatric osteosarcoma – a barrier to the success of immunotherapies in children	Charlotte Chen
4	The Reconstructive Pelvic Anatomy Classification System: A Valid and Reliable Classification System for Pelvic Reconstruction	William Collins
5	Characterising the tumor microenvironment in bony tumours.	Mesalie Feleke
6	Recurrence and prognostic factors of Primary Retroperitoneal Liposarcoma: A Single-Centre Retrospective Cohort Study	Bernard Hanekom
7	Recurrence patterns and Outcomes of Primary Retroperitoneal Leiomyosarcoma: A Single-Centre Retrospective Study	Bernard Hanekom
8	An open-label, phase 1 study to assess safety, tolerability, dosimetry, pharmacokinetics, and imaging properties of ⁸⁹ Zr-olaratumab in patients with soft tissue sarcoma	Angela Hong
9	Advancing CAR-T therapy for paediatric osteosarcoma using a comparative oncology approach	Selvi Jegatheeson
10	Reoperations and recurrence following surgery for myxofibrosarcoma – a major Australian sarcoma centre experience	Mukund Karthik
11	Real World Data of Desmoid Fibromatosis Management in Western Australia: In Particular, Its Response To NSAIDs/Tamoxifen.	Trisha Khoo
12	End-of-Life Symptomology and Palliative Management in Adolescents and Young Adults with Sarcoma and Other Solid Tumours: A Retrospective Study from an Australian Comprehensive Cancer Centre	Kasia Chmiel
13	Outcomes of Resected Retroperitoneal Liposarcoma and Leiomyosarcoma from Royal Prince Alfred Hospital and Chris O'Brien Lifehouse	Alistair McGregor
14	Bone and soft tissue sarcoma - discussing the essential role of specialist nurses in patient care	Hilary Myers

No.	Title	Presenter
15	Priorities in Sarcoma Research for Patients Undergoing Surgery: Perspectives of the Sarcoma Community	Hilary Myers
16	Comparison of Outcomes Based on Patient Geographical Location for Retroperitoneal Sarcoma	Elan Novis (presented by Lylee Ye)
17	REAL-WORLD EXPERIENCE OF CABOZANTINIB MONOTHERAPY IN RELAPSED OR REFRACTORY OSTEOSARCOMA AND EWING SARCOMA: A SINGLE-CENTRE AUSTRALIAN STUDY	Jason Qin
18	REAL-WORLD EXPERIENCE OF SORAFENIB IN DESMOID TUMOURS: A SINGLE-CENTRE AUSTRALIAN STUDY	Jason Qin
19	Systemic Anti –Cancer Therapy (SACT) in patients (pts) with Clear Cell Sarcoma (CCS) or Gastrointestinal Neuroectodermal Tumor (GNET): A Case Series	James Ryan
20	Gnathic intraosseous lipoma of the maxillary sinus – a common diagnosis in a rare location	Sathiyamoorthy Selvarajan
21	Surgical outcomes and cost analysis of multivisceral versus simple resections for retroperitoneal tumours at a highly specialised sarcoma centre	Lylee Ye
22	Referral patterns and recommendations of a retroperitoneal sarcoma MDT: a cohort study of the Sarcoma of the Pelvis, Abdomen, and Retroperitoneum Collaboration (SPARC)	George Mallat (presented by Lylee Ye)
23	Radical surgery for solitary fibrous tumours of the pelvis: a high volume pelvic exenteration centre experience	Evonne Younan
24	Phase 3 Study of Ivosidenib vs Placebo in Locally Advanced or Metastatic IDH1-Mutant Conventional Chondrosarcoma Untreated or Previously Treated with 1 Systemic Treatment Regimen (CHONQUER)	Vladimir Andelkovic

SPONSORS

CONFERENCE DISCLAIMER

Major Sponsors



Limited sponsorship opportunities are available for this event. Please contact us via email at events@aoa.org.au for a copy of the prospectus

The program for this Annual Scientific Meeting (ASM) is correct at the time of publication. However, the Australia and New Zealand Sarcoma Association (ANZSA) reserve the right to change dates, the program and speakers without notice as a result of circumstances beyond its control.

The information contained in any documents and publications contained in the ASM conference package and presentations provided at the ASM (Conference Information) is of a general nature and may have been provided at least in part to ANZSA by third parties. While reasonable care has been exercised to ensure the accuracy of Conference Information, ANZSA, its officers, directors, employees and agents do not make any representation, guarantee or warranty whether express or implied as to the accuracy, reliability, completeness or currency of Conference Information nor its usefulness in achieving any purpose. Conference attendees and ANZSA members are responsible for making their own enquiries as to the accuracy, reliability and completeness of any Conference Information before taking any action based on it.

Conference Information may be amended from time to time. Conference attendees and ANZSA members should make their own enquiries regarding any amendments or alterations to any Conference Information.

Conference Information does not constitute medical or professional advice. Conference attendees and ANZSA members should obtain appropriate medical or professional advice relevant to their own particular circumstances.

To the maximum extent permitted by law, ANZSA does not accept any:

- responsibility for any opinions, advice or information contained in Conference Information, given or otherwise provided at the ASM; or
- liability (direct or indirect) in contract, tort (including negligence) or otherwise for any injury, loss, claim, damage, incidental or consequential damage, arising out of, or in any way connected with, the use of, or reliance on, any Conference Information, or any error, negligent act, omission or misrepresentation in Conference Information and you waive all potential rights against ANZSA in this regard.

ANZSA is committed to diversity and gender equality in healthcare and to removing any practices that hinder that commitment. ANZSA strives to implement this commitment through its policies, practices and inclusive culture. It is an expectation that every individual who attends an ANZSA meeting is respected and treated equally regardless of their cultural background, gender, role or particular circumstance. Adherence to this expectation extends to invited speakers/presenters who are required to develop and review the content of their presentation/s to ensure they meet ANZSA's commitment. ANZSA reserves the right to remove Conference Information or prohibit a presenter from presenting at the ASM if the content of the presenter's Conference Information does not adhere to these requirements. Any complaints about discrimination will be dealt with by the Professional Conduct and Standards Moderator (admin@ANZSA.org.au).

ANZSA will be taking photos at this event. These images may be used in ANZSA internal publications and published on the ANZSA website and ANZSA social media pages. They will be stored securely until they are of no further use, after which they will be deleted.

SCIENTIFIC PROGRAM



ANZSA
Australia and New Zealand
Sarcoma Association

2025 ANNUAL SCIENTIFIC MEETING
10-11 OCTOBER 2025
Crowne Plaza, Hobart & Online